Exact Sciences stock leaves Nasdaq after Abbott pays USD 105
Published on 10/04/2026 at 22:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences stock (ISIN US30063P1057) ended its Nasdaq chapter after Abbott paid USD 105 per share in cash on March 23, 2026. Ticker Scout reports that Exact Sciences became a wholly owned Abbott subsidiary after the transaction closed, shifting the company from a listed cancer diagnostics business into Abbott's Cancer Diagnostics operation.
USD 105 fixed the final value
The cash consideration of USD 105 per share set the final value for Exact Sciences shareholders on March 23, 2026. The transaction also gave Abbott the Cologuard, Oncotype DX and Cancerguard brands, according to Ticker Scout.
For investors, the central change is structural rather than price-driven. Exact Sciences now operates inside Abbott's diagnostics portfolio, so the former EXAS listing no longer provides a separate public-market vehicle for the business.
Revenue beat while EPS stayed negative
Historical fourth-quarter 2025 revenue came to USD 878.4 million, compared with USD 860.9 million expected, a USD 17.5 million beat. IT BOLTWISE reported that adjusted expectations were different on the earnings line: EPS was negative USD 0.45 against a consensus estimate of negative USD 0.11.
That contrast captures the pre-integration profile. Revenue expanded enough to exceed expectations, while the quarterly loss remained material, leaving Abbott to pursue value through scale, distribution and the combination of screening and treatment-guidance products.
Cancer diagnostics moves inside Abbott
Exact Sciences describes its portfolio as covering cancer screening, hereditary-risk testing and genomic analysis after diagnosis. Its website highlights Cologuard, Oncotype DX and Cancerguard as part of the company's broader effort to improve early detection and treatment decisions, according to Exact Sciences.
The strategic logic is clear: Abbott gains a cancer diagnostics platform while Exact Sciences gains access to a larger healthcare distribution network. The key financial reference for the former shareholders remains the USD 105 cash consideration dated March 23, 2026.
Exact Sciences stock has completed its listing
Exact Sciences stock is a completed corporate-action story after the March 23, 2026 acquisition. Its former Nasdaq identity, ticker EXAS, and USD 105 per-share consideration define the final public-market record.
Exact Sciences stock facts
- Company: Exact Sciences Corporation
- ISIN: US30063P1057
- Ticker: EXAS
- Trading venue: Nasdaq, listing ended March 23, 2026
- Sector / Industry: Healthcare / Medical Diagnostics and Research
